R9644
利巴韦林
≥98% (TLC), IMP dehydrogenase inhibitor, powder
别名:
1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H12N4O5
化学文摘社编号:
分子量:
244.20
MDL编号:
UNSPSC代码:
12352202
PubChem化学物质编号:
NACRES:
NA.77
产品名称
利巴韦林, antiviral
质量水平
方案
≥98% (TLC)
表单
powder
溶解性
water: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
抗生素抗菌谱
viruses
作用机制
DNA synthesis | interferes
储存温度
2-8°C
SMILES字符串
NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChI key
IWUCXVSUMQZMFG-AFCXAGJDSA-N
基因信息
human ... IMPDH1(3614), IMPDH2(3615)
正在寻找类似产品? 访问 产品对比指南
一般描述
化学结构：核苷
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。
生化/生理作用
抗病毒剂。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。用于抑制嘌呤（GTP 池）在肌苷单磷酸 (IMP) 脱氢酶级别的生物合成，并作为抑制病毒RNA依赖性RNA聚合酶的二磷酸和三磷酸的前体。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂，但也有实验证据支持许多其他作用机制。
警示用语：
Danger
危险声明
危险分类
Muta. 2 - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
M Colombo et al.
Gut, 63(7), 1150-1158 (2013-11-10)
Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and
Tao Meng et al.
Journal of virology, 88(10), 5803-5815 (2014-03-14)
In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp
Marie Pellerin et al.
Viruses, 13(3) (2021-04-04)
Hepatitis E virus (HEV) is considered as an emerging global health problem. In most cases, hepatitis E is a self-limiting disease and the virus is cleared spontaneously without the need of antiviral therapy. However, immunocompromised individuals can develop chronic infection
Michael Manns et al.
Lancet (London, England), 384(9954), 1597-1605 (2014-08-01)
An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection
Chen-Hua Liu et al.
Annals of internal medicine, 159(11), 729-738 (2013-12-04)
Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持